Scientists from the Collegium Medicum of the Nicolaus Copernicus University in Bydgoszcz are starting a clinical trial in the combat against SARS-CoV-2 infection. The project was named PAVIA – from the historical capital of Lombardy, one of the Italian cities most affected by the coronavirus.

The clinical research will be participated by 1.6 thousand persons quarantined because of documented contact with an already sick person. Its purpose is to prevent people who have been exposed to the virus from spreading the disease.

Researchers from the Nicolaus Copernicus University do not want to reveal at the moment how the therapy will be carried out and what medicines will be developed. They explained this by concern for the good of patients. Researchers ensure that the risks associated with the use of substances proposed by scientists are small. These are two drugs well known in cardiology, whose expected side effect is to be antiviral.